Bioserve India is a young biotech organization primarily  centred at oligo synthesis & DNA sequencing related services, utilizing the classic Sanger platforms, as well as the highly advanced Next Generation sequencing platforms for the life science industry-  academic research institutions & clinical diagnostic labs across India.  Spread over 11000 sq ft of area, Equipped with state-of-the-art facilities and technological platforms, Bioserve India is ISO 9001:2015 certified with DSIR recognition since 2005.

Bioserve was recently acquired by ReproCELL Inc, Japan and is poised to expand its services to the Stem cell research components of the life sciences and drug discovery research and clinical markets, utilizing the Stem cell biology expertise of Nobel Prize-winning scientists at ReproCELL Japan. Bioserve has also partnered with ReproCELL USA enables it to provide molecularly annotated biospecimens for pre-clinical and molecular research the Pharmaceutical and clinical research community.

Bioserve’s goal is to provide the Indian scientific research community access to services which enable the highest levels of research and development in today’s rapidly evolving technological landscape.